State of the Art in Therapy for Non-Small Cell Lung Cancer

References

• Jemal, A.; Tiwari, R C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E J.; Thun, M. Cancer Statistics, 2004.CA, Cancer J. Clin. 2004, 54 (1), 8–29.
   PubMed Web of Science ®Google Scholar
• Page, N R.; W., L.; Tierney, R M.; Arquette, M A.; Piccirillo, F J.; Govindan, R. The epidemiology of small cell lung cancer. In ASCO; 2002. Orlando.
   Google Scholar
• Cancer AJCo. AJCC Cancer Staging Handbook, 6th Ed.; Springer, 2002.
   Google Scholar
• Mountain, C F. Revisions in the International System for Staging Lung Cancer.Chest 1997, 111 (6), 1710–1717 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stephens, R J.; Girling, D J.; Bleehen, N M.; Moghissi, K.; Yosef, H M.; Machin, D. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1–2, N1–2, M0 disease. Medical Research Council Lung Cancer Working Party.Br. J. Cancer 1996, 74 (4), 632–639. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Group TLCS. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group.N. Engl. J. Med. 1986, 315 (22), 1377–1381. [CSA]
   PubMed Web of Science ®Google Scholar
• Anonymous. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.Lancet 1998, 352 (9124), 257–263 [ comment]. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Machtay, M.; Lee, J H.; Shrager, J B.; Kaiser, L R.; Glatstein, E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma.J. Clin. Oncol. 2001, 19 (19), 3912–3917., [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holmes, E.; Gail, M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.J. Clin. Oncol. 1986, 4 (5), 710–715. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Feld, R.; Rubinstein, L.; Thomas, P. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.J. Natl. Cancer Inst. 1993, 85 (4), 299–306. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Keller, S M.; Adak, S.; Wagner, H.; Herskovic, A.; Komaki, R.; Brooks, B J.; Perry, M C.; Livingston, R B.; Johnson, D H. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.N. Engl. J. Med. 2000, 343 (17), 1217–1222 [ comment]. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Scagliotti, G V.; Fossati, R.; Torri, V.; Crino, L.; Giaccone, G.; Silvano, G.; Martelli, M.; Clerici, M.; Cognetti, F.; Tonato, M.; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group, I. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer.J. Natl. Cancer Inst. 2003, 95 (19), 1453–1461 [ comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Anonymous. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.BMJ 1995, 311 (7010), 899–909. [CSA]
   PubMed Web of Science ®Google Scholar
• The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.N. Engl. J. Med. 2004, 350 (4), 351–360. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wada, H.; Hitomi, S.; Teramatsu, T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.J. Clin. Oncol. 1996, 14 (4), 1048–1054. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kato, H.; Ichinose, Y.; Ohta, M.; Hata, E.; Tsubota, N.; Tada, H.; Watanabe, Y.; Wada, H.; Tsuboi, M.; Hamajima, N.; Ohta, M.; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.N. Engl. J. Med. 2004, 350 (17), 1713–1721. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hamada, C O.M.; Wada, H.; Fujimura, S.; Kodama, K.; Imaizumi, M.; Nakanishi, Y.; Matsuoka, N. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small cell lung cancer. In ASCO; 2004, New Orleans.
   Google Scholar
• Strauss, G M.H.J.; Maddaus, M A.; Johnstone, D W.; Johnson, E A.; Watson, D M.; Sugarbaker, D J.; Schilsky, R L.; Green, M. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. In ASCO; 2004.
   Google Scholar
• Winton, T L.L.R.; Johnson, D H.; Rigas, J.; Cormier, Y.; Butts, C.; Ding, K.; Seymour, L.; Magoski, N.; Shepherd, F A. A prospective randomised trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer: Intergroup JBR 10. In ASCO; 2004, New Orleans.
   Google Scholar
• Pisters, K M.G.; R., J.; Giroux, D J.; Kris, M.; Putnam, J B.; Roberts, J R.; Johnson, D H.; Crowley, J.; Bunn, P A. Bimodality lung oncology team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer: long term followup of a phase II trial. In ASCO; 2003, Chicago.
   Google Scholar
• Rosell, R.; Gomez-Codina, J.; Camps, C.; Maestre, J.; Padille, J.; Canto, A.; Mate, J L.; Li, S.; Roig, J.; Olazabal, A.; , et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.N. Engl. J. Med. 1994, 330 (3), 153–158 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Roth, J A.; Fossella, F.; Komaki, R.; Ryan, M B.; Putnam, J B., Jr.; Lee, J S.; Dhingra, H.; De Caro, L.; Chasen, M.; McGavran, M.; , et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.J. Natl. Cancer Inst. 1994, 86 (9), 673–680 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Depierre, A.; Milleron, B.; Moro-Sibilot, D.; Chevret, S.; Quoix, E.; Lebeau, B.; Braun, D.; Breton, J.L.; Lemarie, E.; Gouva, S.; Paillot, N.; Brechot, J M.; Janicot, H.; Lebas, F X.; Terrioux, P.; Clavier, J.; Foucher, P.; Monchatre, M.; Coetmeur, D.; Level, M C.; Leclerc, P.; Blanchon, F.; Rodier, J M.; Thiberville, L.; Villeneuve, A.; Westeel, V.; Chastang, C.; French Thoracic Cooperative, G. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.J. Clin. Oncol. 2002, 20 (1), 247–253 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Albain, K S.; Rusch, V W.; Crowley, J J.; Rice, T W.; Turrisi, A T., III; Weick, J K.; Lonchyna, V A.; Presant, C A.; McKenna, R J.; Gandara, D R.; Fosmire, H.; Taylor, S A.; Stelzer, K J.; Beasley, K R.; Livingston, R B. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805.J. Clin. Oncol. 1995, 13 (8), 1880–1892. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Albain, K S.S.; C., B.; Rusch, V.; Turrisi, A T.; Shepherd, F A.; Smith, C.; Gandara, D.; Johnson, D H.; Green, M R.; Miller, R C. In Phase III study of concurrent concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: first outcome analysis of North American Intergroup trial 0139 (RTOG 93-09), World Conference in Lung Cancer, Vancouver, 2003; S4.
   Google Scholar
• Dillman, R O.; Herndon, J.; Seagren, S L.; Eaton, W L., Jr.; Green, M R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.J. Natl. Cancer Inst. 1996, 88 (17), 1210–1215 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dillman, R O.; Seagren, S L.; Propert, K J.; Guerra, J.; Eaton, W L.; Perry, M C.; Carey, R W.; Frei, E F., III; Green, M R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.N. Engl. J. Med. 1990, 323 (14), 940–945 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sause, W.; Kolesar, P.; Taylor, S I.; Johnson, D.; Livingston, R.; Komaki, R.; Komaki, R.; Emami, B.; Curran, W., Jr.; Byhardt, R.; Dar, A R.; Turrisi, A., III. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.Chest 2000, 117 (2), 358–364. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Furuse, K.; Fukuoka, M.; Kawahara, M.; Nishikawa, H.; Takada, Y.; Kudoh, S.; Katagami, N.; Ariyoshi, Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.J. Clin. Oncol. 1999, 17 (9), 2692–2699. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Curran, W., Jr.; Scott, C B.; Langer, C.; Komaki, R.; Lee, J.; Hauser, B.; Movsas, T.; Sause, W.; Cox, J D. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with recurrent unresected stage III NSCLC: RTOG 9410. In ASCO; 2003, Chicago.
   Google Scholar
• Belani, C P. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.Semin. Oncol. 1999, 26 (1 Suppl. 2), 44–54. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vokes, E E. Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.Oncologist 2001, 6 (Suppl. 1), 25–27. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Hoffman, P C.; Cohen, E E.; Masters, G A.; Haraf, D J.; Mauer, A M.; Rudin, C M.; Krauss, S A.; Huo, D.; Vokes, E E. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.Lung Cancer 2002, 38 (1), 65–71. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pierre, F M.P.; Gilles, R.; Pascal, T.; Souquet, P.-J.; Herve, L.; Vergnenegre, A.; Delhoume, J.-Y.; Francois, M. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (GLOT-GFPC NPC 95-01 study). In ASCO; 2003, San Francisco.
   Google Scholar
• Vokes, E E.; Herndon, J E., II; Crawford, J.; Leopold, K A.; Perry, M C.; Miller, A A.; Green, M R. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.J. Clin. Oncol. 2002, 20 (20), 4191–4198. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gaspar, L E. Optimizing chemoradiation therapy approaches to unresectable stage III non–small cell lung cancer.Curr. Opin. Oncol. 2001, 13 (2), 110–115. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gandara, D R.; Chansky, K.; Albain, K S.; Leigh, B R.; Gaspar, L E.; Lara, P N., Jr.; Burris, H.; Gumerlock, P.; Kuebler, J P.; Bearden, J D., III; Crowley, J.; Livingston, R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504.J. Clin. Oncol. 2003, 21 (10), 2004–2010. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Choy, H C.; W., J., Jr.; Scott, C B.; Bonomi, P.; Travis, P.; Haluschak, J.; Belani, C P. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non-small cell lung cancer. In ASCO; 2002, Orlando.
   Google Scholar
• Vokes, E E.H.J.; Kelley, M J.; Watson, D.; Cicchetti, M G.; Green, M R. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer: initial analysis of a randomized phase III trial. In ASCO; 2004, New Orleans.
   Google Scholar
• Saunders, M.; Dische, S.; Barrett, A.; Harvey, A.; Griffiths, G.; Palmar, M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.Radiother. Oncol. 1999, 52 (2), 137–148 [ see comment]. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Belani, C P.W.W.; Johnson, D H.; Wagner, H.; Schiller, J.; Veeder, M.; Mehta, M. Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and IIIB non-small cell lung cancer: phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). In ASCO; 2003, Chicago.
   Google Scholar
• Lau, D.; Crowley, J.; Gandara, D.; Hazuka, M.; Albain, K.; Leigh, B.; Fletcher, W.; Lanier, K.; Keiser, W.; Livingston, R. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.J. Clin. Oncol. 1998, 16 (9), 3078–3081. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Davies, A M.L.; D., H.; Crowley, J.; Leigh, B.; Gandara, D. Concurrent carboplatin/etoposide and radiation followed by paclitaxel consolidation for poor risk stage III non-small cell lung cancer: a Southwest Oncology Group (SWOG) phase II trial (S9712). In ASCO; 2002, Orlando.
   Google Scholar
• Johnson, D H. Chemotherapy for metastatic non-small-cell lung cancer–can that dog hunt?J. Natl. Cancer Inst. 1993, 85 (10), 766–767 [ comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Evans, W K.; Will, B P.; Berthelot, J M.; Wolfson, M C. The economics of lung cancer management in Canada.Lung Cancer 1996, 14 (1), 19–29 [ comment]. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cullen, M H.; Billingham, L J.; Woodroffe, C M.; Chetiyawardana, A D.; Gower, N H.; Joshi, R.; Ferry, D R.; Rudd, R M.; Spiro, S G.; Cook, J E.; Trask, C.; Bessell, E.; Connolly, C K.; Tobias, J.; Souhami, R L. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.J. Clin. Oncol. 1999, 17 (10), 3188–3194 [ comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kelly, K.; Crowley, J.; Bunn, P A., Jr.; Presant, C A.; Grevstad, P K.; Moinpour, C M.; Ramsey, S D.; Wozniak, A J.; Weiss, G R.; Moore, D F.; Israel, V K.; Livingston, R B.; Gandara, D R. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial.J. Clin. Oncol. 2001, 19 (13), 3210–3218. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schiller, J H.; Harrington, D.; Belani, C P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D H.; The Eastern Cooperative Oncology, G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N. Engl. J. Med. 2002, 346 (2), 92–98. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonomi, P.; Kim, K.; Fairclough, D.; Cella, D.; Kugler, J.; Rowinsky, E.; Jiroutek, M.; Johnson, D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.J. Clin. Oncol. 2000, 18 (3), 623–631. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck, J P.S.; E., F.; Lianes, P.; Schramel, F.; Lenz, M.; Debruyne, C.; Giaccone, G. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). In ASCO; 2001, San Francisco.
   Google Scholar
• Scagliotti, G V.; De Marinis, F.; Rinaldi, M.; Crino, L.; Gridelli, C.; Ricci, S.; Matano, E.; Boni, C.; Marangolo, M.; Failla, G.; Altavilla, G.; Adamo, V.; Ceribelli, A.; Clerici, M.; Di Costanzo, F.; Frontini, L.; Tonato, M.; Italian Lung Cancer, P. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.J. Clin. Oncol. 2002, 20 (21), 4285–4291. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fossella, F.; Pereira, J R.; von Pawel, J.; Pluzanska, A.; Gorbounova, V.; Kaukel, E.; Mattson, K V.; Ramlau, R.; Szczesna, A.; Fidias, P.; Millward, M.; Belani, C P. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group.J. Clin. Oncol. 2003, 21 (16), 3016–3024. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Alberola, V.; Camps, C.; Provencio, M.; Isla, D.; Rosell, R.; Vadell, C.; Bover, I.; Ruiz-Casado, A.; Azagra, P.; Jimenez, U.; Gonzalez-Larriba, J L.; Diz, P.; Cardenal, F.; Artal, A.; Carrato, A.; Morales, S.; Sanchez, J J.; de las Penas, R.; Felip, E.; Lopez-Vivanco, G. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.J. Clin. Oncol. 2003, 21 (17), 3207–3213. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rudd, R G.; N., H.; James, L.; Gregory, W.; Eisen, T.; Lee, S M.; Harper, P E.; Spiro, S. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). In ASCO; 2002, Orlando.
   Google Scholar
• Sandler, A. State-of-the-art treatment for advanced non-small-cell lung cancer.Oncology 2003, 17 (12 Suppl. 13), 15–22. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Socinski, M A.; Schell, M J.; Peterman, A.; Bakri, K.; Yates, S.; Gitten, R.; Unger, P.; Lee, J.; Lee, J H; Tynan, M.; Moore, M.; Kies, M S. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.J. Clin. Oncol. 2002, 20 (5), 1335–1343. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Smith, I E.; O'Brien, M E.; Talbot, D C.; Nicolson, M C.; Mansi, J L.; Hickish, T F.; Norton, A.; Ashley, S. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.J. Clin. Oncol. 2001, 19 (5), 1336–1343. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Larsen, H.; Sorensen, J B.; Nielsen, A L.; Dombernowsky, P.; Hansen, H H. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC).Ann. Oncol. 1995, 6 (10), 993–997. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ellis, P A.; Smith, I E.; Hardy, J R.; Nicolson, M C.; Talbot, D C.; Ashley, S E.; Priest, K. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.Br. J. Cancer 1995, 71 (2), 366–370. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sandler, A B.; Nemunaitis, J.; Denham, C.; von Pawel, J.; Cormier, Y.; Gatzemeier, U.; Mattson, K.; Manegold, C.; Palmer, M C.; Gregor, A.; Nguyen, B.; Niyikiza, C.; Einhorn, L H. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.J. Clin. Oncol. 2000, 18 (1), 122–130 [ comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lilenbaum, R C.H.J.; List, M.; Desch, C.; Watson, D.; Holland, J.; Weeks, J C.; Green, M R. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. In ASCO; 2002, Orlando.
   Google Scholar
• Sederholm, C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase II study by the Swedish Lung Cancer Study Group (SLUSG). In ASCO; 2002, Orlando.
   Google Scholar
• Langer, C J.; Manola, J.; Bernardo, P.; Kugler, J W.; Bonomi, P.; Cella, D.; Johnson, D H. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.J. Natl. Cancer Inst. 2002, 94 (3), 173–181. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Elderly Lung Cancer Vinorelbine Italian Study Group T. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer.JNCI Cancer Spectr. 1999, 91 (1), 66–72. [CSA]
   Google Scholar
• Gridelli, C.; Perrone, F.; Gallo, C.; Cigolari, S.; Rossi, A.; Piantedosi, F.; Barbera, S.; Ferrau, F.; Piazza, E.; Rosetti, F.; Clerici, M.; Bertetto, O.; Robbiati, S F.; Frontini, L.; Sacco, C.; Castiglione, F.; Favaretto, A.; Novello, S.; Migliorino, M R.; Gasparini, G.; Galetta, D.; Iaffaioli, R V.; Gebbia, V. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.J. Natl. Cancer Inst. 2003, 95 (5), 362–372. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Huisman, C.; Smit, E F.; Giaccone, G.; Postmus, P E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review.J. Clin. Oncol. 2000, 18 (21), 3722–3730. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shepherd, F A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; Coughlin, S.; Kim, Y.; Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.J. Clin. Oncol. 2000, 18 (10), 2095–2103 [ comment]. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fossella, F V.; DeVore, R.; Kerr, R N.; Crawford, J.; Natale, R R.; Dunphy, F.; Kalman, L.; Miller, V.; Lee, J S.; Moore, M.; Gandara, D.; Karp, D.; Vokes, E.; Kris, M.; Kim, Y.; Gamza, F.; Hammershaimb, L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.J. Clin. Oncol. 2000, 18 (12), 2354–2362. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hanna, N.; Shepherd, F A.; Fossella, F V.; Pereira, J R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T C.Y.; Pless, M.; Muller, T.; Lim, H.-L.; Desch, C.; Szondy, K.; Gervais, R.; Shaharyar, M C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, P A., Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J. Clin. Oncol. 2004, 22 (9), 1589–1597. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fontanini, G.; De Laurentiis, M.; Vignati, S.; Chine, S.; Lucchi, M.; Silvestri, V.; Mussi, A.; De Placido, S.; Tortora, G.; Bianco, A R.; Gullick, W.; Angeletti, C A.; Bevilacqua, G.; Ciardiello, F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.Clin. Cancer Res. 1998, 4 (1), 241–249. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.Clin. Cancer Res. 1997, 3 (4), 515–522. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Salomon, D S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev. Oncol./Hematol. 1995, 19 (3), 183–232. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ritter, C A.; Arteaga, C L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.Semin. Oncol. 2003, 30 (1 Suppl. 1), 3–11. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perez-Soler, R C.A.; Huberman, M.; Karp, D.; Rigas, J.; Hammond, L.; Rowinsky, E K.; Clark, G.; Santabarbara, P.; Bonomi, P. Final results from a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small lung cancer following failure of platinum-based chemotherapy. In IASLC; Elsevier: Vancouver, 2003.
   Google Scholar
• Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.-Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.-P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J. Clin. Oncol. 2003, 21 (12), 2237–2246. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kris, M G.; Natale, R B.; Herbst, R S.; Lynch, T J., Jr.; Prager, D.; Belani, C P.; Schiller, J H.; Kelly, K.; Spiridonidis, H.; Sandler, H.; Albain, K S.; Cella, D.; Wolf, M K.; Averbuch, S D.; Ochs, J J.; Kay, A C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA 2003, 290 (16), 2149–2158. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Natale, R S.A.; Maddox, A M.; Hammond, L.; Thomas, R.; Gandara, D R.; Gerstein, H.; Panella, T J.; Cole, J.; Jahanzeb, M.; Kash, J.; Hamm, J.; Langer, C J.; Saleh, M.; Stella, P J.; Heyes, A.; Helms, L.; Ochs, J.; Averbuch, S.; Wolf, M.; Kay, A. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD 1839 (Iressa) in IDEAL 2. In ASCO; 2002, Orlando.
   Google Scholar
• Douillard, J G.G.; Horai, T.; Noda, K.; Vansteenkiste, I.; Takata, I.; Gatzemeier, U.; Fukuoka, M.; Macleod, A.; Feyereislova, A.; Averbuch, S.; Nogi, Y.; Heyes, A.; Baselga, J. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD 1839 (Iressa) (IDEAL 1). In ASCO; 2002, Orlando.
   Google Scholar
• Shepherd, F A.P.J.; Ciuleanu, T E.; Tan, E H.; Hirsh, V.; Thongprasert, S.; Bezjak, A.; Tu, D.; Santabarbara, P.; Seymour, L. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemothearpy. A National Cancer Institute of Canada Clinical Trials Group trial. In Proc. Am. Soc. Clin. Oncol., 2004. [CSA]
   Google Scholar
• Herbst, R S.; Giaccone, G.; Schiller, J H.; Natale, R B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J A.; Wolf, M K.; Krebs, A D.; Averbuch, S D.; Ochs, J S.; Grous, J.; Fandi, A.; Johnson, D H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2.J. Clin. Oncol. 2004, 22 (5), 785–794. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Giaccone, G.; Herbst, R S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R B.; Schiller, J H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J S.; Averbuch, S D.; Wolf, M K.; Rennie, P.; Fandi, A.; Johnson, D H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1.J. Clin. Oncol. 2004, 22 (5), 777–784. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Herbst, R S.P.D.; Hermann, R.; Miller, V.; Fehrenbacher, L.; Hoffman, P.; Johnson, B E.; Sandler, A.; Mass, R.; Johnson, D H. TRIBUTE—a phase III trial of erlotinib HCL (OSI-774) combinedwith carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. In ASCO; 2004, New Orleans.
   Google Scholar
• Gatzemeier, U P.A.; Szczesna, A.; Kaukel, E.; Roubec, J.; Brennscheidt, U.; DeRosa, F.; Mueller, B.; von Pawel, J. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. In ASCO; 2004, New Orelans.
   Google Scholar
• Johnson, D H.; Arteaga, C L. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?J. Clin. Oncol. 2003, 21 (12), 2227–2229. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miller, V A.; Kris, M G.; Shah, N.; Patel, J.; Azzoli, C.; Gomez, J.; Krug, L M.; Pao, W.; Rizvi, N.; Pizzo, B.; Tyson, L.; Venkatraman, E.; Ben-Porat, L.; Memoli, N.; Zakowski, M.; Rusch, V.; Heelan, R T. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.J. Clin. Oncol. 2004, 22 (6), 1103–1109. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• West, H F.; W., A.; Gumerlock, P.; Vance, R.; Lau, D.; McCoy, J.; Crowley, J.; Gandara, D. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer: Southwest Oncology Group Study S0126. In ASCO; 2004, New Orleans.
   Google Scholar
• Kris, M S.A.; Miller, V.; Cespon, M.; KZakowski, M.; Pizzo, B.; Venkatraman, E.; Gomez, J.; Johnson, D.; Carbone, D. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma. In ASCO; 2004, New Orleans.
   Google Scholar
• Paez, J G.; Janne, P A.; Lee, J C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F J.; Lindeman, N.; Boggon, T J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M J.; Sellers, W R.; Johnson, B E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science 2004, 304 (5676), 1497–1500. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lynch, T J.; Bell, D W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R A.; Brannigan, B W.; Harris, P L.; Haserlat, S M.; Supko, J.; Haluska, F G.; Louis, D N.; Christiani, D C.; Settleman, J.; Haber, D A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N. Engl. J. Med. 2004, 350 (21), 2129–2139. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• DeVore, R F.L.; Herbst, R S.; Langer, C.; Kelly, K.; Gaudreault, E.; Holmgren, E.; Novotny, W.; Kabbinavar, F. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC. In ASCO; 2000.
   Google Scholar
• Hurwitz, H F.L.; Cartwright, T.; Hainsworth, J D.; Heim, W.; Berlin, J.; Griffing, S.; Novotny, W.; Holmgren, E.; Kabbinavar, F. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-flourouracil, leukovorin) as first-line therapy in subjects with metastatic colorectal cancer. In ASCO; 2003, Chicago.
   Google Scholar